NCT02175654View on ClinicalTrials.gov

Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Colorectal NeoplasmsMetastatic Disease
Interventions
DRUG

Regorafenib

Trial Locations (1)

28046

Spanish Cooperative Group for Digestive Tumour Therapy (TTD), Madrid

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

OTHER

NCT02175654 - Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab | Biotech Hunter | Biotech Hunter